Coronavirus Disease 2019 (COVID-19) remains a global health crisis, despite the development and success of vaccines in certain countries. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, uses its spike protein to bind to the human cell surface receptor angiotensin-converting enzyme 2 (ACE2), which allows the virus to enter the human body. Using our unique cell screening technology, we identified two ACE2-binding peptoid compounds and developed dimeric derivatives (ACE2P1D1 and ACE2P2D1) that effectively blocked spike protein-ACE2 interaction, resulting in the inhibition of SARS-CoV-2 pseudovirus entry into human cells. ACE2P1D1 and ACE2P2D1 also blocked infection by a D614G mutant pseudovirus. More importantly, these compounds do not decrease ACE2 expression nor its enzyme activity (which is important in normal blood pressure regulation), suggesting safe applicability in humans
【저자키워드】 SARS-CoV-2, ACE2 receptor, peptoids, 【초록키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, ACE2, Vaccine, coronavirus, Human, Infection, severe acute respiratory syndrome Coronavirus, virus, angiotensin-converting enzyme 2, Spike protein, Health crisis, Health, pseudovirus, D614G, SARS-CoV-2 pseudovirus, mutant, respiratory, ACE2 expression, Angiotensin-converting enzyme, Interaction, angiotensin, blood pressure, Safe, human body, cell surface receptor, acute respiratory syndrome, Regulation, normal blood pressure, acute respiratory syndrome coronavirus, enzyme, Compound, human cells, these compounds, enzyme activity, applicability, derivative, surface receptor, human cell, Cell, decrease, resulting, blocked, unique, these compound, cause, dimeric, 【제목키워드】 ACE2, block,